Xellia Pharmaceuticals, a specialty pharmaceutical company, has broken ground for a new $10-million expansion of its manufacturing facility in Budapest, Hungary, to include product stability and release-testing capabilities.

The new facility is located next to Xellia’s active pharmaceutical ingredient plant, which currently has 200 employees. On completion in the summer of 2017, the building will house microbiology and chemical analytical laboratories as well as administrative offices. The comany plans to add 80 new positions in manufacturing, product testing, and quality assurance.

The Centralized Laboratory Services building will play an important part in Xellia’s global operational strategy to strengthen its product release and stability testing services for finished dosage forms and active pharmaceutical ingredients that are produced across the company’s other international sites.

Source: Xellia Pharmaceuticals

Source: Xelia Pharmaceuticals